医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Video of Mannatech’s Pure Aloe “Manapol Powder” Available on Business Wire’s Website

2017年04月07日 AM01:36
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

GUANGZHOU, China

A video is available on Business Wire’s Website featuring Mannatech®, Incorporated’s pure aloe product, Manapol® powder, the foundation of Mannatech’s nutritional supplement technology in China.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170406006024/en/

In this video, Mannatech’s CEO and President, Alfredo “Al” Bala, and Senior Global Wellness Director, Dr. Steve Nugent, talk about Mannatech’s Manapol powder as the purest and best source of aloe vera’s healthful properties. Manapol is a powerful element included in Mannatech’s Glyconutritional technology that is part of nearly all of its supplement products available in China through its cross-border e-commerce website, www.MeiTaiChina.com. † This includes its top selling product in China, Advanced Ambrotose®, which is fortified with Manapol and is clinically proven to boost the immune system, support digestive function and support cognitive function, including memory, mood and concentration.

Watch the video to learn more.

† Mannatech’s cross-border e-commerce model in China is a different opportunity from Mannatech’s MLM business in other markets. Customers who invite other customers to the Mannatech China cross-border e-commerce site gain rewards for future product purchases or cash redemption. The e-commerce business model is not multi-level marketing or direct selling.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170406006024/en/

CONTACT

Mannatech, Incorporated
Kalyn Dabbs, 972-471-7245
pr@mannatech.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™